Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

about

Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats

Item

http://www.wikidata.org/entity/Q36203979

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@ast

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@en

type

Item

label

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@ast

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@en

prefLabel

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@ast

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@en

P1476

Short-Term Therapy with Rosigl ...... n in Nonobese Lean Wistar Rats

@en

P2093

Abdul-Razak Abubakari

http://www.w3.org/2001/XMLSchema#string

Ebrahim K Naderali

http://www.w3.org/2001/XMLSchema#string

Imose Itua

http://www.w3.org/2001/XMLSchema#string

Mohammad M Naderali

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

Banting lecture 1988. Role of insulin resistance in human disease

Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products.

Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.

Rosiglitazone reduces blood pressure in female Dahl salt-sensitive rats

Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans

Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect.

Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.

P304

130347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5402/2012/130347

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230812447

http://www.w3.org/2001/XMLSchema#string

P698

22957269

http://www.w3.org/2001/XMLSchema#string

P932

3432376

http://www.w3.org/2001/XMLSchema#string